Catalent Pharma Solutions
14 Schoolhouse Road
Somerset, NJ 08873
T 732 537 6200
F 732 537 6252
www.catalent.com
+1-888 SOLUTION (76588466)
July 25, 2019
Ms. Sasha Parikh
Mr. Rolf Sundwall
Office of Healthcare and Insurance
United States Securities and Exchange Commission Division of Corporate Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: | Catalent, Inc. |
Form10-K for the Fiscal Year Ended June 30, 2018 |
Filed August 28, 2018 |
Form10-Q for the Quarterly Period Ended December 31, 2018 |
Filed February 5, 2019 |
Form10-Q for the Quarterly Period Ended March 31, 2019 |
Filed May 7, 2019 |
FileNo. 001-36587 |
Dear Ms. Parikh and Mr. Sundwall:
This letter follows up on the conversation my colleague Jose Ibietatorremendia had with Ms. Parikh regarding the letter (the “Letter”), dated July 11, 2019, from the staff (the “Staff”) of the United States Securities and Exchange Commission (the “Commission”) to Catalent, Inc. (the “Company”) with respect to the above-referenced Form 10-K and Forms 10-Q. The Company continues to work diligently on a comprehensive response to the Letter and expects to provide the Staff with its response by August 8, 2019. As requested, this letter has been filed with the Commission as correspondence through EDGAR.
Should any question arise in connection with this letter, please contact me at732-537-6169.
Sincerely yours,
/S/ WETTENY JOSEPH
Wetteny Joseph
Senior Vice President & Chief Financial Officer
Catalent, Inc.